38 results about "Golgi protein" patented technology

The invention provides a sandwich enzyme-linked immuno sorbent assay (ELISA) quantitative detection method of Golgi protein GP73. Two strains of monoclonal antibodies aiming at different epitopes of a GP73 extracellular domain are used as a coated antibody and a detection antibody; and the GP73 content is detected through substrate developing and a standard curve. A sandwich ELISA quantitative detection kit of the GP73 comprises the coated antibody, the detection antibody, sealing solution, washing buffer, a color reagent, stop solution and a standard substance, wherein the coated antibody and the detection antibody are two strains of monoclonal antibodies aiming at different epitopes of the GP73 extracellular domain; and the amino acid sequences of proteins recognized by the monoclonal antibodies are shown as SEQ ID No. 1 and SEQ ID No. 2 respectively. Through the sandwich ELISA quantitative detection method and the sandwich ELISA quantitative detection kit of the GP73, the sensitivity and the specificity for detecting the GP73 are improved, high stability and reproducibility are guaranteed, the operating time is shortened and the cost is reduced.

The invention relates to a novel pneumonosis serum marker, namely a Golgi protein gp73, which belongs to the biological monitoring technical field. The invention also discloses an application of the serum Golgi protein gp73 in diagnosing pneumonosis and provides a detection kit for the serum gp73.

The invention relates to an anti-Golgi protein antibody and an application thereof. The invention recombines human GP73 protein immunity animal to obtain an anti-GP73 polyclonal antibody and a monoclonal antibody which specifically aims at GP73 and builds a plurality of methods for detecting GP73 in clinical tissue sections and serum samples, such as immunohistochemical stain and double antibody sandwiched ELISA method and the like. Tests prove that the polyclonal and monoclonal antibodies can be used for preparing a plurality of GP73 detecting agents of different detecting methods.

The invention discloses a prepack eccentric column of fucosido-fucosyl Golgi protein 73 (or Golgi protein 73 heterogeneous body) relative to liver cancer separation, which is characterized by the following: comprising upper separator tube and lower collecting pipe; packing affinity agent of coupling small lentils agglutinine (LCA); assembling a filter cloth on the bottom of the upper separator tube; packing buffer solution in lower collecting pipe; binding small lentils agglutinine (LCA) and sugar chain fucosido-fucosyl Golgi protein 73; centrifuging through adding into eluent; proceeding purify Fuc-GP73 part. This invention discloses a chemoluminescence testing agent case with the eccentric column and enzyme joint immunoassay agent case with the column and preparing and using method. This agent case can test the content of liver cancer fucosido-fucosyl Golgi protein 73, which can provide support for early stage diagnosis.

The invention relates to the field of diagnosis and treatment of liver cirrhosis and liver fibrosis, in particular to application of Golgi protein 73(GP73) and matter for detecting the concentration of the Golgi protein 73(GP73) in preparation of products for screening or auxiliarily diagnosing liver cirrhosis or liver fibrosis related diseases or products for auxiliarily judging prognosis of the diseases. It is proved that the Golgi protein 73(GP73) can serve as a novel liver cirrhosis marker, also has diagnosis value on liver cirrhosis caused by non-b hepatitis virus infection, and has no diagnosis value on primary liver cancer.

The invention provides a protein micro-array kit for early diagnosis of liver caner as well as a preparation method and an application thereof. The kit can be used for monitoring of development level of chronic hepatitis and prognosis, as well as early diagnosis of the liver cancer. The kit can be used for monitoring expression levels of alpha-fetoprotein, alpha-fetoprotein variant, Golgi protein GP73 and Golgi protein GP73 variants, and determining the prognosis level of a patient and the probability of causing cirrhosis and the liver cancer, thereby providing a direct support for the prevention, diagnosis and treatment of the liver cancer and the hepatitis.

The invention relates to a magnetic micro-particle chemiluminiscence detection kit for determining the content of Golgi body protein of a human body. The kit comprises a Golgi body protein R1 reagent,a Golgi body protein R2 reagent, a magnetic separation reagent, a calibrator solution series and a chemiluminiscence substrate solution, wherein the Golgi body protein R1 reagent is an anti-Golgi body protein mouse monoclonal antibody diluent marked by fluorescein isothiocyanate, the Golgi body protein R2 reagent is an alkaline phosphatase marked Golgi body protein polyclonal antibody diluent, the magnetic separation reagent is a magnetic micro-particle diluent coated by an anti-fluorescein isothiocyanate mouse monoclonal antibody, the Golgi body protein calibrator solution is composed of a synthesized Golgi body protein antigen and a buffer solution, and the luminescent substrate solution is a Tris-HCl buffer solution which is catalyzed by alkaline phosphatase and contains dioxacycloethane. According to the invention, the signal intensity and sensitivity of immune response are greatly improved, and a more accurate, accurate, convenient, rapid and simple method is provided for the detection of the Golgi body protein.

The invention relates to use of serum markers containing alpha fetal protein (AFP), Golgi protein 73 (GP73) and carcinoembryonic antigen associated cell adhesion molecule 1 (CEACAM1) in diagnosis of liver diseases. Specifically, the invention provides use of reagents containing an associative part of at least one specific binding AFP, an associative part of at least one specific binding GP73 and an associative part of at least one specific binding CECAM1 protein in preparation of kits for diagnosis and/or prognosis of the liver diseases.

The present invention discloses a Golgi protein-73 mini-ELISA detection system comprising a kit, a portable fluorescence detector, a magnet plate and a magnetic bead carrier, wherein the kit comprises a sample diluent, a washing buffer, an antibody diluent, a Blocking buffer, a chromogenic reagent, a stop solution, a bead activator, a GP73 standard, Golgi protein-73 recognization monoclonal antibody 5F10 and horse radish peroxidase-labeled Golgi protein-73 recognization monoclonal antibody 5B12. The invention also discloses a using method of the detection system. The Golgi protein-73 mini-ELISA detection system does not require the use of a microplate reader, and can be used in relevant units being lack of large equipment. The system can be used to complete the entire testing process on the basis of an immunomagnetic bead serum GP73 double monoclonal antibody sandwich ELISA test kit by combination of a portable fluorescence detector, testing cost is low, and operation is simple and efficient.

The present invention relates to a method for treating breast cancer in a subject having a breast cancer of the triple-negative type, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2). The present invention also relates to a method for treating breast cancer in a subject having a breast cancer over-expressing the “SHP2 signature” genes, as compared to normal breast tissue samples, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2), wherein said “SHP2 signature” genes consist of the genes SGCB, ZSCAN12, ID4, ZIC3, CPVL, HLA-A, MCOLN3, SPATA18, TMEM45A, GNAL, CYBRD1, TSPAN7, ZEB1, CNTLN, NEFL, CENPV, ARL6, HPRT1, LRRC34, PDPN, BEND7, SLC16A10, FAM27E1, PLEKHA1, HERC5, CHIC1, PHF6, ELOVL4, ANTXR1, PRAME, SCML1, CLIP4, CECR2, CNOT10, IGF2BP3, NAP1L3, GPC3, KIAA1804, DGKE, FAS, EPHA6, KDELC1, CRISPLD1, DOCK3, ACSL4, CNTNAP3, PLEKHM3, RDX, TBX18, RRAGD, HOXB5, SNCA, FUNDC2, ITGA8, HFM1, IGF2BP2, CCND2, SGTB, MKX, CRYBG3, WBP5, LPHN3, BEX4, CPNE8, GLDC, SLC35F1, HOXA13, SERPINF1, NEFM, SYCP2L, FHL1, APOBEC3C, CALD1, FKBP10, HOXD11, DENND2C, LRRC49, FAM55C, KIAA0408, HOXB9, C160RF62, ACN9, TUSC3, ELOVL2, SPOCK3, HOXB6, WDR35, MPP1, FBX038, PRKAA2, SLAIN1, NPHP3, KIAA1524, PRPS1, GJC1, AMOT, SLC9A6, KCTD12, NUP62CL, DZIP3, JAM3, HOXA9, ANKRD19, CDKN2A, BCAT1, OAT, LPHN2, CCDC82, HSD17B11, SAMHD1, WDR17, STK33, GSTP1, TRPC1, CKB, LIN28B, ALDH1L2, SACS, CLGN, MY03A, EPB41L3, SLC25A27, VCAN, GPX8, GALNT13, PVRL3, MOXD1, HEY1, MAP7D3, ESD, MPP6, EYA4, SPG20, ZDBF2, ZNF204, IFT57, AKR1B1, ADAT2, ZNF717, CCDC88A, ZNF215, MIDI, FBN2, LOC100130876, TCEAL8, IGF2BP1, ANKRD18B, PLAGL1, PM20D2, LDHB, C150RF51, PTPN11, EPB41L2, TLE4, GOLM1, C60RF192, HOXD13, SLIT2, UCHL1, DYNC2H1, CPS1, GPR180, PYGL, NRN1, PRTFDC1, SLC16A1, DSC3, TMC01, LRCH2, SLC6A15, DZIP1, HOXA5, HSPA4L, CDR1, PLS3, ECHDC1, SMARCA1, CXORF57, HOXD10, and IRS4.

The invention provides a method for detecting Golgi protein 73 (GP73) by using an electrochemical/colorimetric dual-mode sensor based on H-rGO-Mn3O4 nano-enzyme, which comprises the following steps: modifying a screen-printed electrode by using gold nanoparticles (Au NPs), and fixing a complementary chain (cDNA) of a GP73 aptamer (Apt) on the surface of the electrode; the Apt is fixed on the surface of the H-rGO-Mn3O4 nano enzyme to serve as a detection probe; the electrochemical/colorimetric dual-mode aptamer sensor based on the H-rGO-Mn3O4 nano-enzyme is constructed by utilizing the competitive effect between cDNA and a detection probe and between GP73 and the detection probe, adopting 3, 3 ', 5, 5'-tetramethyl benzidine (TMB) as an electrochemical and colorimetric dual-function probe and utilizing a nano-enzyme catalytic signal amplification mode, dual-signal detection of GP73 is realized, and the lowest detection limit is 0.1 pg/mL.